Goldman Sachs Group Inc Recursion Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,539,704 shares of RXRX stock, worth $9.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,539,704

Previous 1,070,550 43.82%

Holding current value

$9.85 Million

Previous $8.03 Million 26.37%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $2.78 Million - $4.03 Million	469,154 Added 43.82%	1,539,704 $10.1 Million
Q2 2024 Aug 13, 2024	BUY	$7.35 - $10.05 $1.28 Million - $1.74 Million	173,530 Added 19.35%	1,070,550 $8.03 Million
Q1 2024 May 15, 2024	SELL	$9.13 - $15.52 $2.69 Million - $4.58 Million	-294,785 Reduced 24.73%	897,020 $8.94 Million
Q4 2023 Feb 13, 2024	BUY	$5.09 - $10.79 $2.68 Million - $5.69 Million	527,032 Added 79.28%	1,191,805 $11.8 Million
Q3 2023 May 14, 2024	SELL	$6.59 - $15.86 $3.47 Million - $8.36 Million	-527,032 Reduced 44.22%	664,773 $5.09 Million
Q3 2023 Nov 14, 2023	BUY	$6.59 - $15.86 $575,491 - $1.39 Million	87,328 Added 15.12%	664,773 $5.09 Million
Q2 2023 May 14, 2024	BUY	$4.56 - $9.94 $192,970 - $420,640	42,318 Added 7.91%	577,445 $4.31 Million
Q2 2023 Aug 14, 2023	BUY	$4.56 - $9.94 $192,970 - $420,640	42,318 Added 7.91%	577,445 $4.31 Million
Q1 2023 May 14, 2024	SELL	$6.42 - $9.64 $307,357 - $461,515	-47,875 Reduced 8.21%	535,127 $3.57 Million
Q1 2023 May 11, 2023	SELL	$6.42 - $9.64 $307,357 - $461,515	-47,875 Reduced 8.21%	535,127 $3.57 Million
Q4 2022 May 14, 2024	BUY	$7.16 - $12.7 $1.61 Million - $2.86 Million	224,936 Added 62.82%	583,002 $4.49 Million
Q4 2022 Feb 13, 2023	BUY	$7.16 - $12.7 $1.61 Million - $2.86 Million	224,936 Added 62.82%	583,002 $4.49 Million
Q3 2022 May 14, 2024	BUY	$7.83 - $13.6 $1.27 Million - $2.2 Million	161,999 Added 82.62%	358,066 $3.81 Million
Q3 2022 Nov 10, 2022	BUY	$7.83 - $13.6 $1.27 Million - $2.2 Million	161,999 Added 82.62%	358,066 $3.81 Million
Q2 2022 May 14, 2024	SELL	$5.04 - $9.26 $5.02 Million - $9.22 Million	-995,738 Reduced 83.55%	196,067 $1.6 Million
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.26 $67,243 - $123,546	-13,342 Reduced 6.37%	196,067 $1.6 Million
Q1 2022 May 16, 2022	BUY	$6.16 - $18.03 $528,669 - $1.55 Million	85,823 Added 69.44%	209,409 $1.5 Million
Q4 2021 Feb 14, 2022	BUY	$16.14 - $21.86 $1.69 Million - $2.29 Million	104,919 Added 562.06%	123,586 $2.12 Million
Q3 2021 Nov 10, 2021	BUY	$19.03 - $41.33 $355,233 - $771,507	18,667 New	18,667 $429,000

Others Institutions Holding RXRX

# of Institutions

289

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.16B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Recursion Pharmaceuticals, Inc. Transaction History